16 Best Mid Cap Growth Stocks To Buy Now

14. United Therapeutics Corporation (NASDAQ:UTHR)

Market Capitalization as of September 13: $15.09 billion

Number of Hedge Fund Holders: 42

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company and public benefit corporation that develops novel, life-extending technologies for patients in the areas of lung disease and organ manufacturing. The focus is to improve the lives of patients with chronic and life-threatening conditions.

The company sees its business as 3 waves of success: First, approved products that are market leaders for the mid-2020s. Second, next-generation products and new indications can be market leaders in the late 2020s. And third, an organ manufacturing business that can transform the treatment of end-stage organ disease.

With this focus, United Therapeutics Corporation (NASDAQ:UTHR) generated $714.90 million in revenue, with a year-over-year improvement of 19.85%. The earnings per share were $5.85. It experienced significant global revenue growth across key products like Tyvaso, Orenitram, Remodulin, and Unituxin.

Tyvaso remains the leading prescribed prostacyclin treatment in the US when combining nebulizer and dry powder inhaler delivery systems. In Q2, Tyvaso generated $398 million in revenue, up 25% from last year. Orenitram reported record revenue at $107 million, up 13% growth, driven by a combination of increased commercial utilization, pricing, and a modest increase in average dose from prior quarter levels. Remodulin revenue was $147 million, up 16% from last year. Unituxin revenue of $47 million was up 18%.

With robust demand and effective pricing strategies, the company is well-positioned for sustained growth and continued success in serving its patients.